Phase I
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.
Up to 40% of AD patients were found to have Lewy Bodies in their brain after succumbing to the disease.
PRESS RELEASES